PRCT - PROCEPT BioRobotics Corporation
[url="]Robbins LLP[/url] informs investors that a securities class action has been filed on behalf of all purchasers of PROCEPT BioRobotics Corporation (NASDAQ:
SAN DIEGO--(BUSINESS WIRE)---- $PRCT #Medicine--Robbins LLP informs investors that a securities class action has been filed on behalf of all purchasers of PROCEPT BioRobotics Corporation (NASDAQ: PRCT) common stock between February 28, 2024 and February 25, 2026, inclusive (the "Class Period").Investors who suffered significant losses during the Class Period may be eligible to participate in the lawsuit and should contact Robbins LLP for information about becoming lead plaintiff.Why Was PROCEPT Sued?The complaint a.
SAN DIEGO, July 24, 2026 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers of PROCEPT BioRobotics Corporation (NASDAQ: PRCT) common stock between February 28, 2024 and February 25, 2026, inclusive (the “Class Period”), have until September 22, 2026 to seek appointment as lead plaintiff of the Procept class action lawsuit. Captioned Operating Engineers Construction Industry and Miscellaneous Pension Fund v.
SAN JOSE, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the second quarter of 2026 after market close on Tuesday, August 4, 2026. The Company's management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.
Pre-Market Stock Futures: Futures are trading higher after a dreadful day on Wall Street, when all the major indices traded lower, and we saw the same pattern that has developed over the last week. The "Buy the Dip" traders come in, briefly get an uptick, and a move higher, and the sellers swarm in to... Here Are Thursday's Best Wall Street Analyst Research Calls: Callaway Golf, Chewy, CME Group, Danaher, General Dynamics, Intel, SpaceX, Rocket Lab, Toast, and More
SAN JOSE, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (Nasdaq: PRCT) today announced two milestones in its WATER IV prostate cancer clinical program: completion of enrollment in the randomized WATER IV study evaluating Aquablation® therapy versus radical prostatectomy, and FDA Investigational Device Exemption (IDE) approval for a second randomized protocol evaluating Aquablation therapy versus active surveillance.
SAN JOSE, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® (Nasdaq: PRCT) today highlighted the latest update to the American Urological Association (AUA) Guidelines for the management of lower urinary tract symptoms (LUTS) attributed to benign prostatic hyperplasia (BPH), which strengthen the recommendation for Aquablation therapy (Robotic Waterjet Treatment) as a surgical treatment option for men with prostate volumes 30–80 mL.
PROCEPT BioRobotics Corporation (PRCT) Presents at Bank of America Global Healthcare Conference 2026 Transcript
SAN JOSE, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, announced today that members of management will present at three upcoming investor conferences in May and June.
PROCEPT BioRobotics Corporation (PRCT) Q1 2026 Earnings Call Transcript
PROCEPT BioRobotics Corporation (PRCT) came out with a quarterly loss of $0.56 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to a loss of $0.45 per share a year ago.
SAN JOSE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended March 31, 2026.
This surgical robotics firm develops minimally invasive systems for urologic procedures, targeting hospitals and specialty clinics.
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, continues its investigation on behalf of PROCEPT BioRobotics Corporation (“Procept” or the “Company”) (NASDAQ: PRCT) investors concerning the Company's possible violations of the federal securities laws.IF YOU ARE AN INVESTOR WHO LOST MONEY ON PROCEPT BIOROBOTICS CORPORATION (PRCT) CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.What Happened?On Februa.
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith continues its investigation on behalf of PROCEPT BioRobotics Corporation (“Procept” or the “Company”) (NASDAQ: PRCT) investors concerning the Company's possible violations of federal securities laws.IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN PROCEPT BIOROBOTICS CORPORATION (PRCT), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.Contact the Law Offices of Howard G. Smith to discuss.
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz continues its investigation of PROCEPT BioRobotics Corporation (“Procept” or the “Company”) (NASDAQ: PRCT) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON PROCEPT BIOROBOTICS CORPORATION (PRCT), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is The Investigation About? On February 25, 2026, Procept reported f.
SAN JOSE, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the first quarter of 2026 after market close on Wednesday, April 29, 2026. The Company's management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.
OPKO Health (NASDAQ: OPK - Get Free Report) and PROCEPT BioRobotics (NASDAQ: PRCT - Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, earnings and analyst recommendations. Earnings and Valuation This table compares OPKO
SG Americas Securities LLC boosted its stake in PROCEPT BioRobotics Corporation (NASDAQ: PRCT) by 142.0% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 84,294 shares of the company's stock after purchasing an additional 49,457 shares during the
Procept BioRobotics reported one set of numbers to investors -- the actual figures told a different story NEW YORK, April 1, 2026 /PRNewswire/ -- Investors in Procept BioRobotics (NASDAQ: PRCT) lost more than 15% of their investment value after the Company disclosed financial results that diverged sharply from the figures management had presented. Those who suffered losses are encouraged to submit their information here.